https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/cannabidiol-trial-shows-reduction-seizures-children-dravet-syndrome/
Cannabidiol trial shows reduction in seizures for children with Dravet syndrome
30 May 2017, 12:58 p.m.
A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.
The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.
In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.
The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.
Read the press release.
Young people donate tissue samples to unlock mysteries of arthritis
A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.
Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.
Genes may help to predict which children will respond well to arthritis treatment
A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.
Making it easier to invest in frontline care
GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.